PersistenceMarketResearch states that the global Aquaculture autogenous vaccine market will witness a CAGR of 5.5% between 2020 and 2030.
It is a known fact that vaccination is amongst the effective tools to avert animal diseases and also to promote safe production of food products, animal welfare and health, and public health. Several epizootic diseases could be brought under control by veterinary vaccines. The current scenario asks for advances in vaccinology and vaccines, so as to pave the way for valuable opportunities for discovering novel candidates for rendering protection against fish pathogens (not just virus and bacteria but parasitic and mycotic agents as well). This factor is there to boost the aquaculture autogenous vaccine market going forward.
Read More to get info: https://www.persistencemarketresearch.com/market-research/autogenous-vaccines-market.asp
The fish species include Cyprinus Carpio, Salmon, Cyclopterus Lumpus, Trout, Sea Bass, Labris Bergylta, Bream, and Tilapia. The pathogen attacking aquatic species are viruses and bacteria. The end-users of aquaculture autogenous vaccines include aquatic research institutes and fish farming companies.
North America and Europe collectively hold more than 30% of the aquaculture autogenous vaccine market. The Asia-Pacific is expected to grow at the fastest pace as fish farming is taking the shape of an “organized sector” therein. Though China is already the major revenue generator, countries like India are flourishing on this count.
The key players in the aquaculture autogenous vaccine market include Bioniche Animal Health, Virbac, Heska Co., Elcano Animal Health, Bayer Healthcare, Boehringer Ingelheim, Merial (Sanofi), Merck Animal Health, Ceva, and Zoetis (Pfizer). Rui Lan An Swine Vaccine from Zoetis is used to cure highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS).
